论文部分内容阅读
自第一个质子泵抑制剂(PPI)奥美拉唑于1988年上市以来,PPI已成为酸相关性疾病治疗的首选药物。PPI抑制胃壁细胞泌酸的最终环节,抑酸能力大大超过H2受体拮抗剂等传统抑酸药,临床应用广泛。近年来PPI研发不断创新,新一代PPI在治疗胃食管反流病及其他酸相关性疾病时具有明显优势,起效更快,抑酸效果更好、更彻底,夜间酸突破短,药物代谢对CYP2C19酶的依赖性小,不受其基因多态性的影响。
PPI has become the drug of choice for the treatment of acid-related diseases since the first Proton Pump Inhibitor (PPI), omeprazole, was introduced in 1988. PPI inhibition of gastric acid secretion in the final part of the cell wall, acid suppression capacity greatly exceeds the H2 receptor antagonists and other traditional acid-suppressing drugs, a wide range of clinical applications. In recent years, continuous research and development of PPI innovation, a new generation of PPI in the treatment of gastroesophageal reflux disease and other acid-related diseases has obvious advantages, faster onset, better acid suppression effect, more thorough, acid breakthrough at night short, drug metabolism The CYP2C19 enzyme is less dependent on its genetic polymorphisms.